Shots:

• Lilly to present results from a long-term study that evaluated the efficacy of Olumiant (4mg- qd) in patients with mod. to sev. RA for 3yrs. of treatment. The study measured LDA as measured by SDAI ≤11- in DMARD-naïve patients and patients with an inadequate response to MTX from treatment initiation to 3yrs.
• The study found that among patients with an inadequate response to MTX- 52% of patients initially treated with Olumiant + MTX were in a state of SDAI LDA @24wks. and the rate is maintained @148wks. Lilly will also present an updated safety analysis of Olumiant in the treatment of RA utilizing data from 3-770 patients taking medicine for up to 8.4yrs.
• Additionally- Lilly will present analyses from an investigational trial evaluating Olumiant in patients with SLE at EULAR. Further- data from P-II JAHH study will be highlighted- which observed whether SLE patients experienced changes in their serum cytokine levels- following Olumiant (4mg)

Click here to read full press release/ article | Ref: Eli Lilly | Image: D&P Event